Axogen, Inc. to report 2024 fourth quarter and full year financial results on February 25, 2025
February 11, 2025 16:58 ET
|
Axogen, Inc.
ALACHUA, Fla. and TAMPA, Fla., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries,...
Axogen Announces Appointment of Jesse Bishop as Vice President of Regulatory Affairs and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
February 03, 2025 08:00 ET
|
Axogen, Inc.
ALACHUA, Fla. and TAMPA, Fla., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries,...
Axogen Announces New VP of Operations and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
January 10, 2025 17:00 ET
|
Axogen, Inc.
ALACHUA, Fla. and TAMPA, Fla., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries,...
Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2024
January 10, 2025 08:00 ET
|
Axogen, Inc.
ALACHUA, Fla. and TAMPA, Fla., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries,...
Axogen, Inc Reports Third Quarter 2024 Financial Results and Provides BLA Update
November 07, 2024 07:00 ET
|
Axogen, Inc.
ALACHUA, Fla. and TAMPA, Fla., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries,...
Axogen, Inc. to report third quarter 2024 financial results and host conference call on November 7, 2024
October 24, 2024 07:00 ET
|
Axogen, Inc.
ALACHUA, Fla. and TAMPA, Fla., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries,...
Axogen Completes Submission of Biologics License Application to U.S. Food and Drug Administration for Avance Nerve Graft®
September 06, 2024 07:00 ET
|
Axogen, Inc.
ALACHUA, Fla. and TAMPA, Fla., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve...
Axogen Reports Inducement Grant to New Employee Under NASDAQ Listing Rule 5635(C)(4)
September 03, 2024 07:00 ET
|
Axogen, Inc.
ALACHUA, Fla. and TAMPA, Fla., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve...
Axogen, Inc. Announces New Leadership Appointments
August 08, 2024 07:05 ET
|
Axogen, Inc.
The Board of Directors appoints Michael Dale as new CEO and Director, effective August 9, 2024Dale replaces Karen Zaderej, who will remain in an advisory role for nine monthsCurrent Member of the...
Axogen, Inc. Reports Second Quarter 2024 Financial Results
August 08, 2024 07:00 ET
|
Axogen, Inc.
ALACHUA, Fla. and TAMPA, Fla., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries,...